MergerAug 19, 2026, 09:21 AM
Chemomab, Scipher Merge; Nebokitug RA Trial Planned
AI Summary
Chemomab Therapeutics announced its second quarter 2026 financial results, reporting a net loss of $3.94 million. The company's primary focus remains on the proposed merger with Scipher Medicine, which is advancing with an expected closing by year-end. This strategic combination aims to leverage Scipher's AI platform to develop Chemomab's lead drug candidate, nebokitug, for rheumatoid arthritis, a significant market with unmet needs. The combined entity will be valued at $150 million before a $30 million private placement, with projected cash runway through the Phase 2 readout. Chemomab shareholders will also receive contingent value rights.
Key Highlights
- Chemomab and Scipher Medicine to merge in an all-stock transaction, forming a combined company valued at $150M before a $30M private placement.
- Combined company to focus on advancing nebokitug in a Phase 2 clinical trial for rheumatoid arthritis, with results expected H1 2028.
- Scipher's AI platform identified nebokitug as a top candidate for RA, a $24B market with significant unmet need.
- Chemomab shareholders to receive contingent value rights (CVRs) for future cash payments based on nebokitug's regulatory approval or PSC program advancement.
- Post-merger, the combined company will operate as Scipher Medicine Corporation and trade on Nasdaq under ticker 'SCIP'.
- Net loss for Q2 2026 was $3.94M, compared to $5.38M in Q2 2025. Total assets decreased to $10.24M from $13.81M.
Price Impact
More from CMMB